Tempest Reports Year End 2021 Financial Results and Provides Business Update
29 mars 2022 16h00 HE
|
Tempest Therapeutics
First clinical data presentation planned for ASCO: TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization armsTPST-1120 randomized study in first-line HCC patients with partner...
Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
10 mars 2022 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
08 mars 2022 16h30 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference
09 févr. 2022 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
18 nov. 2021 08h00 HE
|
Tempest Therapeutics
Combination based on both strong mechanistic rationale and preclinical data SOUTH SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage...
Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
12 nov. 2021 07h00 HE
|
Tempest Therapeutics
Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
10 nov. 2021 16h05 HE
|
Tempest Therapeutics
First patients dosed in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (“HCC”) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La RocheExclusive rights to...
Tempest to Present at Two Upcoming Investor Conferences in November
09 nov. 2021 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...
Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495
08 nov. 2021 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
01 oct. 2021 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that...